Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +33.64%
#3 Cysic Cysic +15.00%
#4 Fabric Protocol Fabric Protocol +9.87%
#5 Perle Perle +8.90%
#6 Bedrock Bedrock +8.53%
#7 Biconomy Biconomy +4.22%
#8 The Black Bull The Black Bull +3.95%
#9 Cap Cap +3.80%
#10 BOOK OF MEME BOOK OF MEME +3.69%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Anatara Lifesciences Ltd Anatara Lifesciences Ltd

Anatara Lifesciences Ltd

ANR
Rank in Stocks #37961
Anatara Lifesciences Ltd is an Australian enterprise focused on researching,... Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression. In the animal health sector, Anatara provides Detach for treating diarrhea in piglets, BONIFF as an enhanced dry feed formulation for weaned piglets, and ANR-pf, a unique additive for poultry drinking water. This company was founded in 2010 and is headquartered in Carlton, Australia.
Share Price
$0.00634756
Last synced: 2026-08-14
Market Cap
$1.32M
Change (1 day)
0.00%
Change (1 year)
39.40%
Country
AU
Trade Anatara Lifesciences Ltd (ANR)

Category

Healthcare
Revenue for Anatara Lifesciences Ltd (ANR)
Revenue in Aug 2026 TTM: 0
According to Anatara Lifesciences Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Anatara Lifesciences Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE